0001209191-20-024246.txt : 20200413
0001209191-20-024246.hdr.sgml : 20200413
20200413183754
ACCESSION NUMBER: 0001209191-20-024246
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200409
FILED AS OF DATE: 20200413
DATE AS OF CHANGE: 20200413
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EHRLICH JASON
CENTRAL INDEX KEY: 0001754049
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38682
FILM NUMBER: 20789621
MAIL ADDRESS:
STREET 1: 2631 HANOVER STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kodiak Sciences Inc.
CENTRAL INDEX KEY: 0001468748
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270476525
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2631 HANOVER STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94304
BUSINESS PHONE: 650-281-0850
MAIL ADDRESS:
STREET 1: 2631 HANOVER STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94304
FORMER COMPANY:
FORMER CONFORMED NAME: Oligasis, LLC
DATE OF NAME CHANGE: 20090721
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-04-09
0
0001468748
Kodiak Sciences Inc.
KOD
0001754049
EHRLICH JASON
2631 HANOVER STREET
PALO ALTO
CA
94304
0
1
0
0
See Remarks
Common Stock
2020-04-09
4
M
0
15000
A
37542
D
Common Stock
2020-04-09
4
F
0
4058
50.67
D
33484
D
Common Stock
2020-04-09
4
S
0
938
47.5394
D
32546
D
Common Stock
2020-04-09
4
S
0
345
48.7046
D
32201
D
Common Stock
2020-04-09
4
S
0
917
49.5478
D
31284
D
Restricted Stock Units
2020-04-09
4
M
0
15000
0.00
D
Common Stock
15000
15000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock.
Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of 25% of the Reporting Person's restricted stock units granted on October 9, 2018. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e).
These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. These sales were made to cover tax withholding obligations in connection with vesting and settlement of 25% of the Reporting Person's RSU granted on October 9, 2018.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $47.095 to $48.045, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $48.185 to $49.00, inclusive.
The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $49.29 to $49.83, inclusive.
50% of the RSU vested 12 months after October 9, 2018 (the "Grant Date"), 25% of the RSU vested 18 months after the Grant Date and 25% of the RSU vest 24 months after the Grant Date.
Chief Medical Officer and Chief Development Officer
/s/ Carlton Fleming, Attorney-in-Fact for Jason Ehrlich
2020-04-13